Study of immune response induced by autologous dendritic cell vaccines in breast cancer patients for the development of new therapeutic strategies (Q3136907): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Breast cancer is an immunogenic tumor and its infiltration by immune system cells provides predictive and prognostic information. In the context of neoadjuvant, the presence of a predominant lymphocyte phenotype in the initial diagnostic biopsy and in the residual tumor correlates with increased patient survival. At our center we have conducted a clinical trial of autologous dendritic cell vaccination in patients with non-metastatic breast canc...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Study of immune response induced by autologous dendritic cell vaccines in breast cancer patients for the development of new therapeutic strategies | |||
Revision as of 13:40, 12 October 2021
Project Q3136907 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Study of immune response induced by autologous dendritic cell vaccines in breast cancer patients for the development of new therapeutic strategies |
Project Q3136907 in Spain |
Statements
40,000.0 Euro
0 references
80,000.0 Euro
0 references
50.0 percent
0 references
1 January 2017
0 references
31 March 2020
0 references
UNIVERSIDAD DE NAVARRA
0 references
42°49'6.42"N, 1°38'39.34"W
0 references
31201
0 references
El cáncer de mama es un tumor inmunogénico y su infiltración por células del sistema inmune aporta información predictiva y pronóstica. En el contexto de la neoadyuvancia, la presencia de un fenotipo linfocitario predominante en la biopsia diagnóstica inicial y en el tumor residual, se correlaciona con una mayor supervivencia de las pacientes. En nuestro centro hemos llevado a cabo un ensayo clínico de vacunación con células dendríticas autólogas en pacientes con cáncer de mama no metastático, para evaluar la eficacia de la combinación de vacunas con la quimioterapia neoadyuvante. Nuestros datos preliminares confirman que las vacunas incrementan las respuestas patológicas completas así como la infiltración linfocitaria por CD8 en el tumor residual. Sin embargo los resultados podrían mejorarse. Sin embargo, pueden existir mecanismos de regulación ó de escape inmunológico del tumor, y por tanto la respuesta generada no ser suficientemente eficaz. Nuestro objetivo principal es estudiar la respuesta inmune humoral y celular inducida por el tratamiento combinado, 1) in vitro mediante proliferación linfocitaria y citotoxicidad e 2) in vivo tanto en sangre periférica como en el tumor; e identificar si existen cambios inducidos por las vacunas en el tumor y su estroma que justifiquen la combinación de la terapia celular con otras estrategias como anticuerpos inmunomoduladores, que por su mecanismo de acción podrían potenciar el efecto inducido por las vacunas. (Spanish)
0 references
Breast cancer is an immunogenic tumor and its infiltration by immune system cells provides predictive and prognostic information. In the context of neoadjuvant, the presence of a predominant lymphocyte phenotype in the initial diagnostic biopsy and in the residual tumor correlates with increased patient survival. At our center we have conducted a clinical trial of autologous dendritic cell vaccination in patients with non-metastatic breast cancer, to evaluate the effectiveness of the combination of vaccines with neoadjuvant chemotherapy. Our preliminary data confirm that vaccines increase complete pathological responses as well as CD8 lymphocyte infiltration into the residual tumor. However, the results could be improved. However, there may be mechanisms of regulation or immune escape from the tumor, and therefore the response generated is not sufficiently effective. Our main objective is to study the humoral and cellular immune response induced by combination therapy, 1) in vitro by lymphocyte proliferation and cytotoxicity and 2) in vivo in peripheral blood and tumor; and identify whether there are changes induced by vaccines in the tumor and its stromal that justify the combination of cell therapy with other strategies such as immunomodulatory antibodies, which by its mechanism of action could enhance the effect induced by vaccines. (English)
12 October 2021
0 references
Pamplona/Iruña
0 references
Identifiers
PI16_01245
0 references